BR112018006547A2 - anticorpos de pd-1 e usos dos mesmos - Google Patents

anticorpos de pd-1 e usos dos mesmos

Info

Publication number
BR112018006547A2
BR112018006547A2 BR112018006547-1A BR112018006547A BR112018006547A2 BR 112018006547 A2 BR112018006547 A2 BR 112018006547A2 BR 112018006547 A BR112018006547 A BR 112018006547A BR 112018006547 A2 BR112018006547 A2 BR 112018006547A2
Authority
BR
Brazil
Prior art keywords
antibodies
present
methods
tcr
expressing
Prior art date
Application number
BR112018006547-1A
Other languages
English (en)
Inventor
Gu Nana
Shao Ke
Original Assignee
Asia Biotech Pte. Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asia Biotech Pte. Ltd filed Critical Asia Biotech Pte. Ltd
Publication of BR112018006547A2 publication Critical patent/BR112018006547A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção proporciona anticorpos monoclonais que se ligam especificamente à pd-1 humana com alta afinidade. as moléculas de ácido nucleico que codificam os anticorpos da invenção, vectores de expressão, células hospedeiras e métodos para expressar os anticorpos da invenção são também proporcionadas. os anticorpos de pd-1 da presente invenção inibem a ligação de pd-l1 a pd-1, modulando assim as respostas imunes em geral e as mediadas por tcr e cd28, em particular. a invenção também proporciona métodos para o tratamento de várias doenças, incluindo doenças infecciosas e câncer, usando os anticorpos de pd-1 da presente invenção.
BR112018006547-1A 2015-09-29 2016-09-29 anticorpos de pd-1 e usos dos mesmos BR112018006547A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234076P 2015-09-29 2015-09-29
US62/234,076 2015-09-29
PCT/SG2016/050482 WO2017058115A1 (en) 2015-09-29 2016-09-29 Pd-1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112018006547A2 true BR112018006547A2 (pt) 2018-12-11

Family

ID=58427739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006547-1A BR112018006547A2 (pt) 2015-09-29 2016-09-29 anticorpos de pd-1 e usos dos mesmos

Country Status (9)

Country Link
US (1) US10981991B2 (pt)
EP (1) EP3356416B1 (pt)
JP (1) JP6952028B2 (pt)
KR (1) KR20180083318A (pt)
CN (1) CN108368175B (pt)
BR (1) BR112018006547A2 (pt)
CA (1) CA3000638C (pt)
RU (1) RU2722451C1 (pt)
WO (1) WO2017058115A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
BR112018003186A2 (pt) 2015-09-01 2018-09-25 Agenus Inc. anticorpos anti-pd-1 e seus métodos de uso
CA2997963A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
MX2019007848A (es) 2017-01-20 2019-09-09 Tayu Huaxia Biotech Medical Group Co Ltd Anticuerpos anti-pd-1 y usos de los mismos.
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
CN110167959A (zh) * 2017-11-30 2019-08-23 盖立复诊断解决方案公司 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白
EP3755716A4 (en) * 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd ANTI-PD-1 ANTIBODIES AND THEIR USES
KR102558418B1 (ko) * 2018-04-15 2023-07-24 임비라 컴퍼니 리미티드 Pd-1에 결합하는 항체 및 그 용도
KR20200143689A (ko) * 2018-04-15 2020-12-24 살루브리스 (청두) 바이오테크 코., 리미티드 Pd-1 결합 항체 및 그의 용도
US20210301024A1 (en) * 2018-07-04 2021-09-30 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
EP3823991A4 (en) * 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF
CA3116564A1 (en) * 2018-11-19 2020-05-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pd-1 antibodies and uses thereof
CN111423510B (zh) * 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
KR20220070201A (ko) * 2019-09-30 2022-05-30 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-pd-1 항체 및 이의 용도
TW202304995A (zh) * 2021-03-31 2023-02-01 荷蘭商美勒斯公司 新穎ｐｄ－１結合域
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10161767T1 (de) * 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
AU2006244885B2 (en) * 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
SI2170959T1 (sl) * 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US9815897B2 (en) * 2013-05-02 2017-11-14 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
CN105683217B (zh) * 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) * 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
DK3081576T3 (da) * 2013-12-12 2019-10-21 Shanghai hengrui pharmaceutical co ltd Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها

Also Published As

Publication number Publication date
WO2017058115A1 (en) 2017-04-06
CN108368175A (zh) 2018-08-03
EP3356416A1 (en) 2018-08-08
US20180282412A1 (en) 2018-10-04
EP3356416A4 (en) 2019-04-10
EP3356416B1 (en) 2021-03-24
CA3000638A1 (en) 2017-04-06
JP2018529368A (ja) 2018-10-11
RU2722451C1 (ru) 2020-06-01
JP6952028B2 (ja) 2021-10-20
US10981991B2 (en) 2021-04-20
KR20180083318A (ko) 2018-07-20
CN108368175B (zh) 2021-08-06
CA3000638C (en) 2024-02-27

Similar Documents

Publication Publication Date Title
BR112018006547A2 (pt) anticorpos de pd-1 e usos dos mesmos
BR112017013385A2 (pt) anticorpos para tigit
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
ZA201905822B (en) Antibodies against pd-l1
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
BR112019003129A2 (pt) composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112018010172A2 (pt) anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112016016699A2 (pt) Anticorpos humanos para pd-1
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
BR112018005164A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
PH12019500571A1 (en) Anti-pd-1 antibodies

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ASIA BIOTECH PTE. LTD (SG)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]